Abstract
We report here a study on efficacy of sevelamer hydrochloride in treating hyperphosphatemia due to tumor lysis syndrome (TLS) in a developing world setting. Twenty one children with hyperphosphatemia due to TLS were included. All received hyper-hydration, allopurinol and sevelamer. Efficacy was assessed by decrease in serum phosphate level, calcium-phosphate product and TLS score as per Cairo Bishop definition. Four children who underwent dialysis were excluded from analysis. Among the remaining 17 patients with hyperphosphatemia, laboratory TLS was recorded in 15 patients and clinical TLS in five. Sevelamer was given according to weight, most often 400mg twice to thrice daily. Mean phosphatemia decreased from 8.3±3.0 to 6.7±2.1mg/dl within 24h of starting sevelamer (p=0.02), 6.0±2.1mg/dl at 48h, 4.9±1.5mg/dl at 72h and 4.39±1.7mg/dl at 96h. TLS was corrected in 72h in 14 patients, 96h in 1 and 120h in another patient. Mean calcium-phosphate product decreased from 63.0±14.0 to 49.2±9.7mg/dl (p=0.002) at 24h, 46.1±17.0mg/dl at 48h and 39.7±13.5mg/dl at 72h. There was no mortality due to hyperphosphatemia. Sevelamer is efficacious in children with malignancy-associated hyperphosphatemia in the developing world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Indian Journal of Hematology and Blood Transfusion
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
